With Moderna shares flying at a pandemic high, the market cap has now pierced the $100B mark, leapfrogging GlaxoSmithKline
Back just before the pandemic hit the world in early 2020, Moderna’s shares were trading right around $20 a share. Today, it’s above $250 a share — up 3% this morning — and the market cap has pierced the $100 billion mark.
Working solo, the biotech high flyer has changed the world and saved lives with its highly effective and apparently safe vaccine for Covid-19, developed in record time. And that’s been worth a valuation that’s close to twice that of the other big mRNA success story: BioNTech, which is partnered with an unabashedly triumphant Pfizer. The Big Pharma partner has shared the profits and the glory with BioNTech, which has seen its own share price soar from around $30 to $217.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,500+ biopharma pros reading Endpoints daily — and it's free.